Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385242
Status:
COMPLETED
Last Update Posted:
2019-11-21
First Post:
2006-10-06
Brief Title:
PET and Recovery Following Revascularization PARR 2
Sponsor:
Ottawa Heart Institute Research Corporation
Organization:
Ottawa Heart Institute Research Corporation
Study Overview
Official Title:
PET and Recovery Following Revascularization Outcome and Cost-effectiveness of FDG PET in Left Ventricular Dysfunction PARR 2
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rationale Patients with severe ventricular dysfunction and coronary disease have high morbidity and mortality They may benefit from revascularization but have significant peri-operative morbidity and mortality Positron emission tomography PET imaging with F-18-fluorodeoxyglucose FDG can detect viable myocardium that may recover from revascularization in such patients It is unclear whether use of FDG PET in this population is improves outcome or is cost-effective
Objectives The principal aim is to determine whether FDG PET-guided therapy is effective versus standard care Secondary objectives are to determine whether FDG PET-guided therapy improves LV function quality of life and is good value for money versus standard care
Objectives The principal aim is to determine whether FDG PET-guided therapy is effective versus standard care Secondary objectives are to determine whether FDG PET-guided therapy improves LV function quality of life and is good value for money versus standard care
Detailed Description:
Patients with severe ventricular dysfunction and coronary artery disease have high morbidity and mortality but may benefit from revascularization However there is also significant peri-operative morbidity and mortality among these patients This accounts for the variable approach to these patients in different cardiac centres Clearly this patient group has the most to gain when coronary revascularization is beneficial but also the most to lose when it is not helpful There is a need for an approach that can better define patients with severe ventricular dysfunction due to ischemia who will be more likely to benefit from revascularization Positron emission tomography PET imaging with F-18-Fluorodeoxyglucose FDG has been used to evaluate patients with ventricular dysfunction to detect ischemic but viable myocardium more likely to recover from revascularization Recently retrospective studies have shown that FDG PET can identify patients at high risk for cardiac events if they do not undergo revascularization However these studies did not evaluate whether FDG PET actually directed therapy decisions and because of their study design could not determine whether FDG PET altered patient outcome Our recent studies have shown that FDG PET can have important impact on therapy decisions and that patients with ischemic but viable myocardium are at increased risk However it remains unclear whether an approach which utilizes FDG PET to define ischemic but viable myocardium can have a beneficial effect on patient outcome It is also important to consider the potential clinical impact of FDG PET balanced against its limited availability In addition despite the cost of the technology preliminary data from our group and others suggest a potential cost savings Accordingly a prospective randomized study is needed to evaluate whether FDG PET directed therapy has a beneficial effect on patient outcome and is cost-effective
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None